For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and Attruby represents a significant breakthrough . These groundbreaking therapies preserve the transthyretin protein, halting its damaging build-up and reducing the impact of